Results 191 to 200 of about 575,997 (353)
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity
KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao +25 more
wiley +1 more source
Hematology clinicopathological exercise
Asmaa Mohammed Thanun
doaj +1 more source
Burnout symptoms among hematology professionals: An EHA survey. [PDF]
Bommier C +7 more
europepmc +1 more source
AMERICAN SOCIETY OF HEMATOLOGY Sixteenth Annual Meeting • Chicago, Illinois • December 1-4, 1973 [PDF]
Antigens Baker +10 more
openalex +1 more source
Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]
et al.,, Hayashi, Robert J, Vig, Ravi
core +1 more source
Glioblastoma (GBM) is the most aggressive primary brain tumor, with glioma stem cells (GSCs) driving treatment resistance. This study reveals that lactate promotes histone lactylation (H3K18la) at the VRK1 promoter, regulating GSC stemness and proliferation via the H3K18la/VRK1/YBX1/SOX2 pathway. The VRK1‐targeted nanoliposome A/TMZ‐siVRK1 demonstrates
Jinna Li +4 more
wiley +1 more source
Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [PDF]
Chanut M +28 more
europepmc +1 more source
AMERICAN SOCIETY OF HEMATOLOGY Seventeenth Annual Meeting • Atlanta, Georgia • December 7-10, 1974 [PDF]
Bensusen Harris +6 more
openalex +1 more source

